ω-Substituted alkyl carboxylic acids as antidiabetic and lipid-lowering agents

被引:10
|
作者
Meyer, K
Voss, E
Neidlein, R
Kühnle, HF
Pill, J
机构
[1] Boehringer Mannheim GmbH, Therapeut Res, D-6800 Mannheim, Germany
[2] Univ Heidelberg, Inst Pharmazeut Chem, D-6900 Heidelberg, Germany
关键词
omega-substituted alkyl carboxylic acids; insulin sensitizer; lipid lowering;
D O I
10.1016/S0223-5234(99)80029-4
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In screening experiments certain omega-substituted alkyl carboxylic acids were found to produce an increase in insulin-stimulated C-14-acetate incorporation into triglycerides, which may indicate an improvement in the action of insulin. Antidiabetic and lipid-lowering properties in genetically diabetic ob/ob mice demonstrated the in vivo relevance of the insulin-potentiating effects seen in vitro. The chemical structures of the w-substituted alkyl carboxylic acids with insulin-potentiating effects correspond to the general formula ring-spacer-COOH. A close structure-activity relationship was observed. The most potent compound in ob/ob mice was 3e, which normalized blood glucose as well as hyperinsulinaemia and lowered serum triglycerides and cholesterol by 52% and 37%, respectively. On the basis of these results, omega-substituted alkyl carboxylic acids are interesting as a new class of oral antidiabetic agents with insulin-sensitizing and lipid-lowering activity. (C) Elsevier, Paris.
引用
收藏
页码:775 / 787
页数:13
相关论文
共 50 条
  • [41] Lipid-lowering agents and fibrinolysis:: lack of effect in vitro
    Elzaher, SM
    Pallister, CJ
    Dunn, CDR
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2001, 58 (04) : 244 - 246
  • [42] Role of lipid-lowering agents in the management of diabetic retinopathy
    Ioannidou, Estelle
    Tseriotis, Vasilis-Spyridon
    Tziomalos, Konstantinos
    WORLD JOURNAL OF DIABETES, 2017, 8 (01) : 1 - 6
  • [44] IMPROVEMENT OF COMPLIANCE WITH LIPID-LOWERING AGENTS IMPROVEMENT OF THE COMPLIANCE OF LIPID-LOWERING MEDICATION. CONTROLLED STUDY IN COMMUNITY PHARMACY
    Andres Iglesias, J. Carlos
    Andres Rodriguez, N. Floro
    Fornos Perez, Jose A.
    FARMACEUTICOS COMUNITARIOS, 2009, 1 (03): : 92 - 98
  • [45] POTENTIAL HYPOLIPIDEMIC AGENTS .20. SYNTHESIS AND LIPID-LOWERING PROPERTIES OF ANNELATED THIOPHENECARBOXYLIC ACIDS
    GRONOWITZ, S
    HERSLOF, M
    SVENSON, R
    BONDESSON, G
    MAGNUSSON, O
    STJERNSTROM, NE
    ACTA PHARMACEUTICA SUECICA, 1978, 15 (05): : 368 - 381
  • [46] The Use of Antidiabetic, Antihypertensive, and Lipid-lowering Medications in the Elderly Dying with Advanced Cancer
    Al-Shahri, Mohammad Zafir
    Sroor, Mahmoud Yassein
    Ghareeb, Wael Ali
    Aboulela, Enas Noshy
    Edesa, Wael
    INDIAN JOURNAL OF PALLIATIVE CARE, 2019, 25 (01) : 124 - 126
  • [47] Synthetic statins: More data on newer lipid-lowering agents
    Wierzbicki, AS
    CURRENT MEDICAL RESEARCH AND OPINION, 2001, 17 (01) : 74 - 77
  • [48] Effects of Lipid-Lowering Agents on Inflammation, Haemostasis and Blood Pressure
    Tziomalos, Konstantinos
    Karagiannis, Asterios
    Athyros, Vasilios G.
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (40) : 6306 - 6313
  • [49] Trends in the use of lipid-lowering agents in an Indonesia's hospital
    Kristin, Erna
    Atthobari, Jarir
    Dwiprahasto, Iwan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S269 - S270
  • [50] Reducing expenditures for statin-type lipid-lowering agents
    Glover, J
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 (10) : 995 - 996